A Study Assessing the Feasibility and Outcomes of Ofatumumab Plus Ifosfamide/Etoposide (OIE) followed by Autologous Stem Cell Transplantation (ASCT) with Carmustine/Etoposide/Cytarabine/Melphalan/Rituximab (BEAM/R) in Patients with Relapsed B-Cell Non-Hodgkin's Lymphomas (NHL)

Trial Profile

A Study Assessing the Feasibility and Outcomes of Ofatumumab Plus Ifosfamide/Etoposide (OIE) followed by Autologous Stem Cell Transplantation (ASCT) with Carmustine/Etoposide/Cytarabine/Melphalan/Rituximab (BEAM/R) in Patients with Relapsed B-Cell Non-Hodgkin's Lymphomas (NHL)

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Carmustine; Cytarabine; Etoposide; Filgrastim; Ifosfamide; Melphalan; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Results assessing the feasibility of peripheral blood stem cell (PBSC) mobilization with G-CSF following ofatumumab with ifosfamide/etoposide, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 23 Jan 2017 New trial record
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top